Tectonic Therapeutic Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 60

Employees

  • Stock Symbol
  • TECX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $20.73
  • (As of Friday Closing)

Tectonic Therapeutic General Information

Description

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 490 Arsenal Way
  • Suite 210
  • Watertown, MA 02472
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 490 Arsenal Way
  • Suite 210
  • Watertown, MA 02472
  • United States

Tectonic Therapeutic Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tectonic Therapeutic Stock Performance

As of 20-Nov-2026, Tectonic Therapeutic’s stock price is $20.73. Its current market cap is $405M with 19.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$20.73 $21.04 $16.77 - $39.53 $405M 19.5M 212K -$4.63

Tectonic Therapeutic Financials Summary

As of 30-Sep-2026, Tectonic Therapeutic has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 232,636 123,225 525,021
Revenue 0 0 0 0
EBITDA (95,448) (82,780) (60,491) (41,774)
Net Income (88,099) (74,151) (57,982) (42,823)
Total Assets 243,860 261,038 152,905 39,399
Total Debt 3,918 1,276 3,303 4,343
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tectonic Therapeutic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tectonic Therapeutic‘s full profile, request access.

Request a free trial

Tectonic Therapeutic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and
Drug Discovery
Watertown, MA
60 As of 2025

Melbourne, Australia

Ghent, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tectonic Therapeutic Competitors (4)

One of Tectonic Therapeutic’s 4 competitors is Certa Therapeutics, a Venture Capital-Backed company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Certa Therapeutics Venture Capital-Backed Melbourne, Australia
Confo Therapeutics Venture Capital-Backed Ghent, Belgium
Longboard Pharmaceuticals Formerly VC-backed La Jolla, CA
Escient Pharmaceuticals Formerly VC-backed San Diego, CA
To view Tectonic Therapeutic’s complete competitors history, request access »

Tectonic Therapeutic Patents

Tectonic Therapeutic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240409601-A1 Relaxin-2 fusion protein analogs and methods of using same Active 18-May-2023
WO-2024238955-A2 Relaxin-2 fusion protein analogs and methods of using same Inactive 18-May-2023
WO-2024238955-A3 Relaxin-2 fusion protein analogs and methods of using same Inactive 18-May-2023
WO-2024044659-A1 Constitutively active g protein-coupled receptor compositions and methods of use thereof Inactive 24-Aug-2022
CA-3237801-A1 Relaxin-2 fusion protein analogs and methods of using same Pending 11-Nov-2021 C07K14/64
To view Tectonic Therapeutic’s complete patent history, request access »

Tectonic Therapeutic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tectonic Therapeutic Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tectonic Therapeutic‘s full profile, request access.

Request a free trial

Tectonic Therapeutic Acquisitions (1)

Tectonic Therapeutic’s most recent deal was a Merger/Acquisition with AVROBIO. The deal was made on 20-Jun-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AVROBIO 20-Jun-2024 Merger/Acquisition Drug Discovery
To view Tectonic Therapeutic’s complete acquisitions history, request access »

Tectonic Therapeutic ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.94 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Tectonic Therapeutic’s complete esg history, request access »

Tectonic Therapeutic FAQs

  • When was Tectonic Therapeutic founded?

    Tectonic Therapeutic was founded in 2019.

  • Where is Tectonic Therapeutic headquartered?

    Tectonic Therapeutic is headquartered in Watertown, MA.

  • What is the size of Tectonic Therapeutic?

    Tectonic Therapeutic has 60 total employees.

  • What industry is Tectonic Therapeutic in?

    Tectonic Therapeutic’s primary industry is Drug Discovery.

  • Is Tectonic Therapeutic a private or public company?

    Tectonic Therapeutic is a Public company.

  • What is Tectonic Therapeutic’s stock symbol?

    The ticker symbol for Tectonic Therapeutic is TECX.

  • What is the current stock price of Tectonic Therapeutic?

    As of 20-Nov-2026 the stock price of Tectonic Therapeutic is $20.73.

  • What is the current market cap of Tectonic Therapeutic?

    The current market capitalization of Tectonic Therapeutic is $405M.

  • Who are Tectonic Therapeutic’s competitors?

    Certa Therapeutics, Confo Therapeutics, Longboard Pharmaceuticals, and Escient Pharmaceuticals are competitors of Tectonic Therapeutic.

  • What is Tectonic Therapeutic’s annual earnings per share (EPS)?

    Tectonic Therapeutic’s EPS for 12 months was -$4.63.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process